Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S)
作者： Terje R. Pedersen , Anders G. Olsson , Ole Færgeman , John Kjekshus , Hans Wedel
DOI: 10.1161/01.CIR.97.15.1453
关键词:
摘要: Background—The Scandinavian Simvastatin Survival Study (4S) randomized 4444 patients with coronary heart disease (CHD) and serum cholesterol 5.5 to 8.0 mmol/L (213 310 mg/dL) triglycerides ≤2.5 (220 simvastatin 20 40 mg or placebo once daily. Over the median follow-up period of 5.4 years, one more major events (MCEs) occurred in 622 (28%) 2223 group 431 (19%) 2221 (34% risk reduction, P<.00001). produced substantial changes several lipoprotein components, which we have attempted relate beneficial effects observed. Methods Results—The Cox proportional hazards model was used assess relationship between lipid values (baseline, year 1, percent change from baseline at 1) MCEs. The reduction MCEs within highly correlated on-treatment levels total LDL cholesterol, apolipoprotein B, an...
sci-hub.se 参考文章(24)
K. PYÖRÄLÄ, G. DE BACKER, I. GRAHAM, P. POOLE-WILSON, D. WOOD, Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. European Heart Journal. ,vol. 15, pp. 1300- 1331 ,(1994) , 10.1093/OXFORDJOURNALS.EURHEARTJ.A060388
Robert A. Wolfe, Robert L. Strawderman, Logical and statistical fallacies in the use of cox regression models American Journal of Kidney Diseases. ,vol. 27, pp. 124- 129 ,(1996) , 10.1016/S0272-6386(96)90039-6
William P. Castelli, Keaven Anderson, Peter W.F. Wilson, Daniel Levy, Lipids and risk of coronary heart disease The Framingham Study Annals of Epidemiology. ,vol. 2, pp. 23- 28 ,(1992) , 10.1016/1047-2797(92)90033-M
Z Chen, R Peto, R Collins, S MacMahon, J Lu, W Li, Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ. ,vol. 303, pp. 276- 282 ,(1991) , 10.1136/BMJ.303.6797.276
Jeremiah Stamler, Is Relationship Between Serum Cholesterol and Risk of Premature Death From Coronary Heart Disease Continuous and Graded? JAMA. ,vol. 256, pp. 2823- 2828 ,(1986) , 10.1001/JAMA.1986.03380200061022
John Kjekshus, Terje R. Pedersen, Reducing the risk of coronary events: Evidence from the Scandinavian Simvastatin survival study (4S) American Journal of Cardiology. ,vol. 76, pp. 64- ,(1995) , 10.1016/S0002-9149(99)80473-1
Scott M. Grundy, Gary J. Balady, Michael H. Criqui, Gerald Fletcher, Philip Greenland, Loren F. Hiratzka, Nancy Houston-Miller, Penny Kris-Etherton, Harlan M. Krumholz, John LaRosa, Ira S. Ockene, Thomas A. Pearson, James Reed, Sidney C. Smith, Reginald Washington, When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction Circulation. ,vol. 95, pp. 1683- 1685 ,(1997) , 10.1161/01.CIR.95.6.1683
Ted P. Szatrowski, Arthur V. Peterson, Yukiko Shimizu, Ross L. Prentice, Mark W. Mason, Yasuo Fukunaga, Hiroo Kato, Serum cholesterol, other risk factors, and cardiovascular disease in a Japanese cohort Journal of Chronic Diseases. ,vol. 37, pp. 569- 584 ,(1984) , 10.1016/0021-9681(84)90007-9
Michael H. Davidson, Evan A. Stein, Carlos A. Dujovne, Donald B. Hunninghake, Stuart R. Weiss, Robert H. Knopp, D.Roger Illingworth, Yale B. Mitchel, Michael R. Melino, Robert V. Zupkis, Michael R. Dobrinska, Raju D. Amin, Jonathan A. Tobert, The Efficacy and Six-Week Tolerability of Simvastatin 80 and 160 mg/Day American Journal of Cardiology. ,vol. 79, pp. 38- 42 ,(1997) , 10.1016/S0002-9149(96)00742-4
J R Patsch, G Miesenböck, T Hopferwieser, V Mühlberger, E Knapp, J K Dunn, A M Gotto, W Patsch, Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arteriosclerosis, Thrombosis, and Vascular Biology. ,vol. 12, pp. 1336- 1345 ,(1992) , 10.1161/01.ATV.12.11.1336